NV-PROOVSTATION
9.1.2020 16:34:11 CET | Business Wire | Press release
Plans are being implemented for up to 40 inspection portals to be deployed across the BCA Group, starting in February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200109005586/en/
At the 2020 CES in Las Vegas, ProovStation and BCA Group, Europe’s leading vehicle remarketing company, today confirmed a commercial agreement to implement ProovStation inspection portals in BCA auctions and logistics compounds across Europe. The roll-out, which is planned to cover 13 countries, will commence in February.
Thanks to industry-leading artificial intelligence, ProovStation portals will allow BCA to carry out a fully automated damage inspection, including underneath the vehicle, within 3 seconds. As the car drives through the portal, even millimeter-large scratches can be spotted, increasing precision and cost-efficiency.
“We are proud to have been chosen by BCA Group as their site based volume inspection partner. The trust from Europe’s largest seller of used cars is a strong signal of legitimacy for ProovStation and confirms the value of our solutions for the automotive industry in its widest definition. This first large contract is a motivation booster for our team, and we will continue to work hard at revolutionising the vehicle inspection process. We want to turn ProovStation into the international standard in the inspection process for the main market segments: OEM, dealers, rental and logistics service providers ” says Cédric BERNARD, CEO of ProovStation.
Jean-Roch PIAT, Divisional CEO of BCA Europe added: “As the leading marketplace for used vehicles across Europe, BCA is providing the power of accurate real-time decision intelligence capability that connects every aspect of buying and selling with BCA, Europe’s largest used vehicle marketplace. ProovStation AI-powered inspection technology allows us to further increase the accuracy of the damage recognition, at unprecedented levels of speed and unit cost to benefit our customers .”
ABOUT PROOVSTATION
ProovStation automates and standardizes the global automotive inspection process. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
OFFICIAL COMMERCIAL LAUNCH AT CES 2020
For its second participation at the CES, the ProovStation start-up returns to Las Vegas with a finalised product, the official launch for mass production, and the determination to win more contracts. ProovStation will present its latest portal at Eureka Park booth 50841.
ABOUT BCA
BCA works with OEMs, fleet operators and dealers to provide the backbone of Europe's automotive supply chain, remarketing 1.4 million vehicles annually.
From technical and logistics services for new vehicles, refurbishment, storage and logistics for the growing used sector and the core remarketing and auction operation, BCA offers the economies of scale and diversity of services to meet the needs of an impressive portfolio of customers.
As the automotive industry faces a period of unprecedented change, BCA is uniquely placed to deliver a range of linked services through the combined infrastructure of de-fleet facilities, vehicle logistics and preparation centres and physical, hybrid and digital remarketing channels.
BCA is investing and innovating today to deliver accurate real-time decision intelligence capability that allow its customers to operate seamlessly in both physical and digital markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005586/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom